Maze Therapeutics to present Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease at ASN Kidney Week 2026

• Maze Therapeutics flagged upcoming presentations on its kidney pipeline at ASN Kidney Week on Oct. 21-25, 2026.
• Previously reported Phase 2 HORIZON results for MZE829 in APOL1-mediated kidney disease will be presented again with added detail.
• The update pointed to encouraging clinical activity, supporting continued development of the lead program.
• Separate preclinical work on MZE782 is set to be shown, backing SLC6A19 inhibition as a potential approach in chronic kidney disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061605PRIMZONEFULLFEED9840861) on October 06, 2026, and is solely responsible for the information contained therein.